Summary
The study is a domestic multicenter, prospective, non-randomized controlled concurrent trial. It will be assessed whether surgery staging on locally advanced cervical cancer is superior to image staging for improving progression-free survival and overall survival.
Key Facts
Lead Sponsor
Enrollment
Start Date
Completion Date
Study Type
Official Title
Interventions
Conditions
Eligibility
Age Range
Sex
Inclusion Criteria: 1. The patients with good compliance, voluntarily signed the informed consent form and participated in the study. 2. Histopathology: squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma 3. Stage (FIGO2018): IB3, IIA2, IIB-IVA; 4. ECOG score: 0 \~ 1; 5. The expected survival \>6 months; 6. The result of a pregnancy test (serum or urine) within seven days must be negative for women of childbearing age, who must take contraception during the trial. Exclusion Criteria: 1. Activity or uncontrol severe infection; 2. Liver cirrhosis or other decompensated liver disease; 3. A history of immune deficiency, including HIV positive or a congenital immunodeficiency disease; 4. Chronic renal insufficiency or renal failure; 5. Other malignancies were diagnosed within five years or needed treatments; 6. Myocardial infarction, severe arrhythmia and congestive heart failure with grade ≥2 (New York heart association); 7. The CT/MRI/PET/CT show that the para-aortic lymph nodes are positive; 8. A history of pelvic artery embolization; 9. A history of pelvic radiotherapy; 10. A history of partial hysterectomy or radical hysterectomy; 11. A history of severe allergic reaction to platinum drugs; 12. The drugs for the treatment of concomitant disease seriously impaired liver or kidney function, such as tuberculosis; 13. Patients who cannot understand the research regimen and refuse to sign the informed consent form; 14. Other concomitant diseases or special conditions seriously endanger the patient's health or interfere with the trial.